Company Profile

Company Overview

Kintai Therapeutics was founded by Flagship Pioneering in 2016 through its venture creation engine, which founded Seres, Moderna, Agios, Indigo and Evelo, to pioneer therapeutics from microbiome metabolites. Integrating discoveries in metabolic pathways and cross-tissue signaling networks, Kintai Therapeutics leverages proprietary chemistry to develop small molecule therapeutics for multiple therapeutic areas including metabolic, inflammatory, and infectious diseases. Kintai Therapeutics has rapidly built a deep pipeline of candidates across a range of therapeutic areas, with the potential to quickly move into the clinic. Kintai Therapeutics offers the challenge and opportunity to work at an innovative early stage company with rapid and nimble growth, combining near stage development candidates with a sustainable pipeline for long term success. Kintai Therapeutics is poised to emerge as the field-defining company in the microbiome metabolite space—one that leading scientists feel should be the dominant means of drugging the microbiome. The company is driven to discover and fully develop novel compounds that extend and improve the lives of individuals with a broad range of serious and potentially devastating diseases.